RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion X1 platform with SCINTIX biology-guided radiotherapy at Beverly Hills Cancer Center (BHCC), the first freestanding cancer center (FSCC) that has installed the RefleXion X1.
“At BHCC, we are committed to advancing cancer care by integrating the latest innovations, ensuring our patients receive the highest quality, cutting-edge treatments,” said Arash (Ari) Gabayan, M.D., Chief of Radiation Oncology and Imaging at Beverly Hills Cancer Center. “We are excited to be amongst the first centers in the world to offer our patients this breakthrough technology, which uses the inherent biology of the patient’s tumor to precisely direct the radiation beam to its tumor target.
“This is a totally new and exciting concept in radiation treatment delivery, and we believe that using the tumor’s own biology will transform how patients are treated,” Dr. Gabayan continued.
The RefleXion X1 machine with SCINTIX therapy is designed to use biology guidance to precisely treat one or more targets within the same treatment session. Early clinical cases have demonstrated that when the tumor moves, SCINTIX therapy autonomously shifts the radiation dose to follow the tumor, thereby safely delivering radiation to the tumor target while sparing radiation exposure to healthy tissue.
“We are thrilled to count BHCC and its world-class cancer physicians among our early customers and as our first freestanding cancer center,” said Todd Powell, president and CEO of RefleXion. “Their commitment to providing access to cutting-edge cancer treatments like SCINTIX therapy is invaluable.”
Beginning in 2025, the Centers for Medicare and Medicaid Services (CMS) will expand reimbursement for SCINTIX therapy, introducing new billing codes for FSCCs and professional reimbursement for physicians in both FSCCs and hospital outpatient departments.
“We are encouraged that CMS has expanded reimbursement for freestanding cancer centers like BHCC as this supports clinicians who advance clinical adoption of new technologies and treatments,” continued Powell.
BHCC physicians consulted with Select Healthcare Solutions, a provider of turn-key medical technology solutions to independent physician groups, to integrate SCINTIX therapy into its comprehensive range of cancer treatment options.
SCINTIX therapy uses signals emitted from a patient’s cancer cells to direct radiation treatment. Patients receive an injection of a small amount of a unique molecule, called a PET tracer, which the cancer cells consume.
The X1 detects the signals produced in real time and uses those to determine where to deliver the radiation dose. In contrast, conventional radiotherapy uses static images of anatomy to guide treatment delivery.
